BR112023006322A2 - Durvalumab adjuvante em combinação com quimioterapia para tratamento de câncer - Google Patents

Durvalumab adjuvante em combinação com quimioterapia para tratamento de câncer

Info

Publication number
BR112023006322A2
BR112023006322A2 BR112023006322A BR112023006322A BR112023006322A2 BR 112023006322 A2 BR112023006322 A2 BR 112023006322A2 BR 112023006322 A BR112023006322 A BR 112023006322A BR 112023006322 A BR112023006322 A BR 112023006322A BR 112023006322 A2 BR112023006322 A2 BR 112023006322A2
Authority
BR
Brazil
Prior art keywords
durvalumab
chemotherapy
combination
cancer
adjuvant
Prior art date
Application number
BR112023006322A
Other languages
English (en)
Inventor
Dennis Phillip
Poole Lynne
May Rena
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023006322A2 publication Critical patent/BR112023006322A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DURVALUMAB ADJUVANTE EM COMBINAÇÃO COM QUIMIOTERAPIA PARA TRATAMENTO DE CÂNCER. A presente invenção refere-se genericamente a métodos para tratar câncer em um paciente usando durvalumab em combinação com quimioterapia com base no estado residual mínimo do paciente. Especificamente, a divulgação se refere a prevenir ou tratar um tumor recorrente em um paciente, em que o paciente é positivo para doença residual mínima (MRD+), usando durvalumab e quimioterapia.
BR112023006322A 2020-10-12 2021-10-11 Durvalumab adjuvante em combinação com quimioterapia para tratamento de câncer BR112023006322A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063090441P 2020-10-12 2020-10-12
PCT/EP2021/078050 WO2022078958A1 (en) 2020-10-12 2021-10-11 Adjuvant durvalumab in combination with chemotherapy for treatment of cancer

Publications (1)

Publication Number Publication Date
BR112023006322A2 true BR112023006322A2 (pt) 2023-05-09

Family

ID=78087371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006322A BR112023006322A2 (pt) 2020-10-12 2021-10-11 Durvalumab adjuvante em combinação com quimioterapia para tratamento de câncer

Country Status (10)

Country Link
US (1) US20230406931A1 (pt)
EP (1) EP4225790A1 (pt)
JP (1) JP2023544635A (pt)
KR (1) KR20230086731A (pt)
CN (1) CN116348141A (pt)
AU (1) AU2021360175A1 (pt)
BR (1) BR112023006322A2 (pt)
CA (1) CA3197479A1 (pt)
IL (1) IL301760A (pt)
WO (1) WO2022078958A1 (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1

Also Published As

Publication number Publication date
IL301760A (en) 2023-05-01
WO2022078958A1 (en) 2022-04-21
CA3197479A1 (en) 2022-04-21
CN116348141A (zh) 2023-06-27
US20230406931A1 (en) 2023-12-21
AU2021360175A1 (en) 2023-06-15
JP2023544635A (ja) 2023-10-24
EP4225790A1 (en) 2023-08-16
AU2021360175A9 (en) 2024-09-05
KR20230086731A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112019021822A2 (pt) Terapia de combinação
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
EA202092154A1 (ru) Комбинированная терапия
CL2023003603A1 (es) Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo ii
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
BR112023006322A2 (pt) Durvalumab adjuvante em combinação com quimioterapia para tratamento de câncer
BR112022017466A2 (pt) Terapia combinada com um inibidor de idh mutante e um inibidor de bcl-2
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
BR112022017491A2 (pt) Método para tratar indivíduos resistentes ao inibidor idh1
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112022022634A2 (pt) Inibidores de atr para o tratamento de câncer
BR112023015440A2 (pt) Métodos de tratamento de câncer usando uma combinação de regimes de dosagem com serd
BR112023025986A2 (pt) Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.